Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.

Brain pathology (Zurich, Switzerland) - 1 Sept 2020

Schrauben Michael, Dempster Emma, Lunnon Katie

Abstract excerpt

Recent studies have highlighted a potential role of genetic and epigenetic variation in the development of Alzheimer's disease. Application of the CRISPR-Cas genome-editing platform has enabled investigation of the functional impact that Alzheimer's disease-associated gene mutations have on gene expression. Moreover, recent advances in the technology have led to the generation of CRISPR-Cas-based tools that allow...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clustered Regularly Interspaced Short Palindromic Repeats
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Epigenesis, Genetic

Share to Epigenomics

Share to Gene Editing

Share to Neurodegenerative Diseases

Share to Technology

Source

Open in PubMed Open full text

Identifiers

PMID: 32654206
DOI: 10.1111/bpa.12881
PMCID: PMC8018012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.PMID 32654206Read ↗

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's DiseaseSemantic proximity Read ↗

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeuticsSemantic proximity Read ↗

Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.Semantic proximity Read ↗

Genetics of Alzheimer's DiseaseSemantic proximity Read ↗

Application of CRISPR/Cas9 in the management of Alzheimer’s disease and Parkinson’s disease: a reviewSemantic proximity Read ↗

Editing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and Plasticity.Semantic proximity Read ↗

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.Semantic proximity Read ↗

High-throughput CRISPRi and CRISPRa technologies in 3D genome regulation for neuropsychiatric diseases.Semantic proximity Read ↗

Advances in epigenetics and epigenomics for neurodegenerative diseases.Semantic proximity Read ↗

CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genesSemantic proximity Read ↗

Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy.Semantic proximity Read ↗

Functional characterization of a single nucleotide polymorphism associated with Alzheimer's disease in a hiPSC-based neuron model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.